Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALGS Aligos Therapeutics	$6.03 +8.1%	$8.78	$3.76 ▼ $46.80	$36.87M	2.72	189,476 shs	124,581 shs
BETRF BetterLife Pharma	$0.07 +10.1%	$0.07	$0.05 ▼ $0.15	$9.06M	1.47	16,664 shs	116,447 shs
KZR Kezar Life Sciences	$4.40 +0.5%	$5.01	$3.62 ▼ $9.18	$32.15M	0.61	58,532 shs	5,237 shs
NRXP NRx Pharmaceuticals	$2.08 -1.9%	$2.04	$1.10 ▼ $6.01	$35.19M	1.41	435,401 shs	74,204 shs

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALGS Aligos Therapeutics	+6.29%	+4.10%	-32.36%	-76.50%	-70.82%
BETRF BetterLife Pharma	-2.00%	-6.47%	-3.49%	-28.38%	-23.28%
KZR Kezar Life Sciences	-0.23%	-4.37%	-10.25%	-32.41%	-46.88%
NRXP NRx Pharmaceuticals	+2.91%	+7.07%	+3.41%	-29.10%	-17.83%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALGS Aligos Therapeutics	3.8907 of 5 stars	3.5	1.0	4.8	2.7	1.7	0.6
BETRF BetterLife Pharma	0.2007 of 5 stars	0.0	3.0	0.0	0.0	1.7	0.0
KZR Kezar Life Sciences	3.9365 of 5 stars	3.2	3.0	4.6	2.2	1.7	0.6
NRXP NRx Pharmaceuticals	2.3281 of 5 stars	3.6	2.0	0.0	3.3	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALGS Aligos Therapeutics	3.00	Buy	$70.00	1,060.86% Upside
BETRF BetterLife Pharma	0.00	N/A	N/A	N/A
KZR Kezar Life Sciences	2.33	Hold	$39.50	797.73% Upside
NRXP NRx Pharmaceuticals	3.20	Buy	$28.50	1,270.19% Upside

Current Analyst Ratings Breakdown

Latest BETRF, ALGS, NRXP, and KZR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/30/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00 ➝ $31.00
4/29/2025	NRXP NRx Pharmaceuticals	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$45.00 ➝ $46.00
4/2/2025	NRXP NRx Pharmaceuticals	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$18.00
3/31/2025	ALGS Aligos Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$70.00 ➝ $70.00
3/31/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00 ➝ $31.00
3/24/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00 ➝ $31.00
3/20/2025	NRXP NRx Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00 ➝ $19.00
3/17/2025	NRXP NRx Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$31.00 ➝ $31.00
3/14/2025	NRXP NRx Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00 ➝ $19.00
3/11/2025	ALGS Aligos Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$75.00 ➝ $70.00
2/28/2025	KZR Kezar Life Sciences	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Outperform

(Data available from 5/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALGS Aligos Therapeutics	$3.95M	9.35	N/A	N/A	$30.65 per share	0.20
BETRF BetterLife Pharma	N/A	N/A	N/A	N/A	($0.05) per share	N/A
KZR Kezar Life Sciences	$7M	4.59	N/A	N/A	$25.80 per share	0.17
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	($1.38) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALGS Aligos Therapeutics	-$87.68M	-$20.90	N/A	N/A	N/A	-1,283.19%	-114.34%	-64.58%	5/6/2025 (Estimated)
BETRF BetterLife Pharma	-$2.14M	-$0.03	N/A	∞	N/A	N/A	N/A	-999.57%	5/27/2025 (Estimated)
KZR Kezar Life Sciences	-$101.87M	-$11.55	N/A	N/A	N/A	N/A	-54.95%	-46.11%	5/8/2025 (Estimated)
NRXP NRx Pharmaceuticals	-$30.15M	-$2.41	N/A	N/A	N/A	N/A	N/A	-449.16%	5/13/2025 (Estimated)

Latest BETRF, ALGS, NRXP, and KZR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	NRXP NRx Pharmaceuticals	-$0.40	N/A	N/A	N/A	N/A	N/A
5/8/2025	Q1 2025	KZR Kezar Life Sciences	-$2.56	N/A	N/A	N/A	N/A	N/A
5/6/2025	Q1 2025	ALGS Aligos Therapeutics	-$2.80	N/A	N/A	N/A	$0.33 million	N/A
3/25/2025	Q4 2024 & Study Result	KZR Kezar Life Sciences	-$2.71	-$2.77	-$0.06	-$2.77	N/A	N/A
3/14/2025	Q4 2024	NRXP NRx Pharmaceuticals	-$0.20	-$0.30	-$0.10	-$0.77	N/A	N/A
3/10/2025	Q4 2024	ALGS Aligos Therapeutics	-$2.63	-$13.08	-$10.45	-$13.08	$0.43 million	$0.63 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALGS Aligos Therapeutics	N/A	N/A	N/A	N/A	N/A
BETRF BetterLife Pharma	N/A	N/A	N/A	N/A	N/A
KZR Kezar Life Sciences	N/A	N/A	N/A	N/A	N/A
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALGS Aligos Therapeutics	N/A	3.81	3.81
BETRF BetterLife Pharma	N/A	0.05	0.05
KZR Kezar Life Sciences	0.05	7.65	7.65
NRXP NRx Pharmaceuticals	N/A	0.20	0.20

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALGS Aligos Therapeutics	60.43%
BETRF BetterLife Pharma	0.01%
KZR Kezar Life Sciences	67.90%
NRXP NRx Pharmaceuticals	4.27%

Insider Ownership

Company	Insider Ownership
ALGS Aligos Therapeutics	8.75%
BETRF BetterLife Pharma	34.77%
KZR Kezar Life Sciences	9.30%
NRXP NRx Pharmaceuticals	19.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALGS Aligos Therapeutics	90	6.11 million	3.27 million	No Data
BETRF BetterLife Pharma	7	129.46 million	84.45 million	Not Optionable
KZR Kezar Life Sciences	60	7.31 million	6.62 million	Not Optionable
NRXP NRx Pharmaceuticals	2	16.92 million	12.72 million	Optionable

BETRF, ALGS, NRXP, and KZR Headlines

Recent News About These Companies

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces FDA Award of Filing Fee Waiver for Upcoming ...

April 30 at 9:34 AM | gurufocus.com

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces FDA Award of Filing Fee Waiver for Upcoming ...

April 30 at 9:34 AM | gurufocus.com

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc.to Participate in an H.C. Wainwright @ Home Fireside Discussion on Tuesday, April 22, 2025

April 21, 2025 | prnewswire.com

BTIG Initiates Coverage of NRx Pharmaceuticals (NRXP) with Buy Recommendation

April 3, 2025 | msn.com

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of a Term Sheet for Strategic Investment from a Global Medical Device Manufacturer into HOPE

April 3, 2025 | prnewswire.com

NRx Pharmaceuticals initiated with a Buy at BTIG

April 3, 2025 | markets.businessinsider.com

NRx Pharmaceuticals’ Hope Therapeutics to acquire Dura Medical, no terms

April 1, 2025 | markets.businessinsider.com

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Definitive Purchase Agreement with Dura Medical; Initial Acquisition for Planned International Network of Interventional Psychiatry Clinics

March 31, 2025 | prnewswire.com

Here's Why NRx Pharmaceuticals (NRXP) Is a Great 'Buy the Bottom' Stock Now

March 27, 2025 | zacks.com

NRx Pharmaceuticals, HOPE Therapeutics sign binding LOI with Neurospa

March 24, 2025 | markets.businessinsider.com

HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of Binding Letter of Intent with Neurospa TMS Holdings, LLC for Expansion of its Planned International Network of Interventional Psychiatry Clinics

March 24, 2025 | prnewswire.com

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q4 2024 Earnings Call Transcript

March 21, 2025 | msn.com

NRx pharmaceuticals files New Drug Application for ketamine depression treatment

March 19, 2025 | greenmarketreport.com

NRx Pharmaceuticals, Inc. (NRXP) Q4 2024 Earnings Call Transcript

March 17, 2025 | seekingalpha.com

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

March 17, 2025 | prnewswire.com

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 17, 2025

March 12, 2025 | prnewswire.com

NRx Pharmaceuticals to Post Q4 Earnings: How to Play the Stock?

March 3, 2025 | zacks.com

NRx Pharmaceuticals, Inc. (NRXP): Among the Best Psychedelic Stocks to Buy in 2025

March 1, 2025 | insidermonkey.com

The Therapeutic Potential and Investment Boom in Psychedelic Medicine

March 1, 2025 | uk.finance.yahoo.com

NRx Pharmaceuticals, Inc. (NRXP): Among the Best Psychedelic Stocks to Buy in 2025

March 1, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BETRF, ALGS, NRXP, and KZR Company Descriptions

Aligos Therapeutics NASDAQ:ALGS

$6.03 +0.45 (+8.06%)

Closing price 04:00 PM Eastern

Extended Trading

$6.13 +0.10 (+1.72%)

As of 07:49 PM Eastern

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

BetterLife Pharma OTCMKTS:BETRF

$0.07 +0.01 (+10.06%)

As of 03:36 PM Eastern

BetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of compounds for the treatment of mental disorders in Canada. It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections. The company's products pipeline includes BETR-001 for the treatment of major depressive disorder, anxiety, and neuropathic pain and other neuro-psychiatric and neurological disorders; and BETR-002 to treat benzodiazepine dependency, anxiety, and neurodegenerative disorders. It is also developing MM-003, which has completed Phase II clinical trials for treatment of COVID-19 and other respiratory viral infections; and MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia that has completed Phase II clinical trials. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.

Kezar Life Sciences NASDAQ:KZR

$4.40 +0.02 (+0.46%)

Closing price 04:00 PM Eastern

Extended Trading

$4.40 +0.00 (+0.11%)

As of 04:05 PM Eastern

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

NRx Pharmaceuticals NASDAQ:NRXP

$2.08 -0.04 (-1.89%)

Closing price 04:00 PM Eastern

Extended Trading

$2.13 +0.05 (+2.60%)

As of 07:59 PM Eastern

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time